The Motley Fool··Prosper Junior BakinyViking Therapeutics Advances Weight-Loss Candidate Into Late-Stage Trials
Viking Therapeutics advances obesity drug VK2735 into Phase 3 trials after positive interim results, positioning itself in the competitive weight-loss pharmaceutical market.
LLYNVOVKTXbiotechweight loss drugs